Skip to main content
Premium Trial:

Request an Annual Quote

Atugen Strikes Contract Research Deal with Eisai Subsidiary

NEW YORK, July 8 (GenomeWeb News) - Atugen said this week that it has signed a contract research agreement with Eisai London Research Laboratories, a subsidiary of Japanese drug maker Eisai.


Under the deal, Atugen will use its gene-silencing technologies to validate and optimize undisclosed drug targets provided by Eisai. Additional terms, including the financials, were not disclosed.


This is Atugen's second research agreement this year with a Japanese pharmaceutical company. The company also announced a multi-year agreement with Sankyo on May 17.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.